Literature DB >> 17038698

Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus.

Andrey A Kolokoltsov1, Eryu Wang, Tonya M Colpitts, Scott C Weaver, Robert A Davey.   

Abstract

Virus envelope proteins are the primary targets of neutralizing antibody responses. The epitopes recognized differ sufficiently between virus subtypes and species to distinguish viruses and provide an important basis for disease diagnosis. Venezuelan equine encephalitis virus (VEEV) causes acute febrile illness in humans and has high mortality in equines. The most specific detection methods for serum antibodies use live virus in neutralization assays or in blocking enzyme linked immunosorbent assays. However, work with Venezuelan equine encephalitis virus requires biosafety level 3 containment and select agent security in the United States. We report two new assays for detection of Venezuelan equine encephalitis virus neutralizing antibody responses, based on virus pseudotypes. The first provides detection by marker gene expression after 20 hours and is particularly suited for high-throughput screening; the second uses a new, rapid virus entry assay to give readouts within 1 hour. Both assays are safe, sensitive, and in general recapitulate neutralizing antibody titers obtained by conventional plaque reduction assays. Each is suitable as a rapid primary screen for detection of neutralizing antibodies against Venezuelan equine encephalitis virus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038698

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  7 in total

1.  Use of sindbis/eastern equine encephalitis chimeric viruses in plaque reduction neutralization tests for arboviral disease diagnostics.

Authors:  B W Johnson; O Kosoy; E Wang; M Delorey; B Russell; R A Bowen; S C Weaver
Journal:  Clin Vaccine Immunol       Date:  2011-07-13

2.  Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening.

Authors:  Andrey A Kolokoltsov; Mohammad F Saeed; Alexander N Freiberg; Michael R Holbrook; Robert A Davey
Journal:  Drug Dev Res       Date:  2009-06-01       Impact factor: 4.360

3.  Development and characterization of an equine infectious anemia virus Env-pseudotyped reporter virus.

Authors:  R L Tallmadge; M A Brindley; J Salmans; R H Mealey; W Maury; S Carpenter
Journal:  Clin Vaccine Immunol       Date:  2008-04-30

Review 4.  Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers.

Authors:  Shuetsu Fukushi; Hideki Tani; Tomoki Yoshikawa; Masayuki Saijo; Shigeru Morikawa
Journal:  Viruses       Date:  2012-10-12       Impact factor: 5.048

5.  Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1.

Authors:  Angeline P C Lim; Steven K K Wong; Annie H Y Chan; Conrad E Z Chan; Eng Eong Ooi; Brendon J Hanson
Journal:  Virol J       Date:  2008-07-11       Impact factor: 4.099

6.  Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library.

Authors:  Angeline P C Lim; Conrad E Z Chan; Steven K K Wong; Annie H Y Chan; Eng Eong Ooi; Brendon J Hanson
Journal:  Virol J       Date:  2008-10-28       Impact factor: 4.099

7.  Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates.

Authors:  Kristen E Pascal; Drew Dudgeon; John C Trefry; Manu Anantpadma; Yasuteru Sakurai; Charles D Murin; Hannah L Turner; Jeanette Fairhurst; Marcela Torres; Ashique Rafique; Ying Yan; Ashok Badithe; Kevin Yu; Terra Potocky; Sandra L Bixler; Taylor B Chance; William D Pratt; Franco D Rossi; Joshua D Shamblin; Suzanne E Wollen; Justine M Zelko; Ricardo Carrion; Gabriella Worwa; Hilary M Staples; Darya Burakov; Robert Babb; Gang Chen; Joel Martin; Tammy T Huang; Karl Erlandson; Melissa S Willis; Kimberly Armstrong; Thomas M Dreier; Andrew B Ward; Robert A Davey; Margaret L M Pitt; Leah Lipsich; Peter Mason; William Olson; Neil Stahl; Christos A Kyratsous
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.